NCT00865072

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

A Relative Bioavailability Study of 750 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Actavis Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750 mg) in healthy adult volunteers under fasting conditions

Detailed description

Study Type: Interventional Study Design: Randomized, single dose, two-way crossover study under fasting conditions Official Title: A Relative Bioavailability Study of 750 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Metformin HCl 750 mg Extender Release tablets, single dose	A: Experimental Subjects received Purepac formulated products under fasting conditions
DRUG	GLUCOPHAGE® XR 750 mg tablets, single dose	B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions

Timeline

• Start date: 2003-08-01
• Primary completion: 2003-08-01
• Completion: 2003-08-01
• First posted: 2009-03-19
• Last updated: 2010-08-17

Locations

1 site across 1 country: United States